Cyclacel Pharmaceuticals, Inc. (CYCCP)
$5.56-5.12%Close
BUYCRISIS · day 1
Key stats
- Market cap
- $12M
- Beta
- 0.16
- Div yield
- 11.88%
- P/E (TTM)
- -1.42
- 1W
- -5.44%
- 1M
- +5.30%
- vs SPY 1W
- -6.60%
- vs SPY 1M
- +2.31%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Dividend Compounder
Composite of Value · Growth · GARP
ROIC-23.4%
REV YoY-
ROE-39.0%
EPS YoY-
ROA-22.2%
GROSS19
OP-122053
NET-90302
[VALUATION]
P/E TTM-1.42
P/E FWD0.01
SECTOR PE20.47
INDUSTRY PE13.95
P/B4.18
P/FCF-
EV/EBITDA1419.65
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.06
ND/EBITDA-
BETA0.16
POTENTIAL YIELD TRAP (YIELD 11.9% WITH PAYOUT/LEVERAGE/GROWTH STRESS)
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on CYCCP?
- LOPJLB’s latest quantitative signal on Cyclacel Pharmaceuticals, Inc. (CYCCP) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is CYCCP in?
- Cyclacel Pharmaceuticals, Inc. (CYCCP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cyclacel Pharmaceuticals, Inc. (CYCCP) do?
- Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for …